P53和P57kip2在脑膜瘤中的表达及临床意义

目的探讨P53和P57kip2在脑膜瘤中的表达及临床意义。方法应用免疫组化SP法检测41例脑膜瘤组织和21例正常脑膜组织中P53和P57kip2蛋白的表达。结果在脑膜瘤中两者的阳性表达率:P53 48.78%,P57kip241.46%;P53在恶性脑膜瘤中的阳性率(75.00%)显著高于良性脑膜瘤及正常组织中的阳性率(P<0.05);P57kip2在恶性脑膜瘤中的阳性率(25.00%)显著低于于良性脑膜瘤及正常组织中的阳性率(P<0.05);P53与P57kip2在脑膜瘤中的表达呈负相关。结论 P53和P57kip2分别是脑膜瘤进展及预后判断的独立指标,多个指标联合检查用来估计患者预后指导意义更佳。     

脑星形细胞瘤癌基因表达

52例星形细胞瘤应用免疫组化方法,检测癌基因p~(53)、C-erbB-2及增殖细胞核抗原(PCNA)的表达,结果发现①p53异常表达率为41.2%(24/52),C-erbB-2过度表达率为39%(20/52),PCNA(PI>0.05)增殖指数为77%(40/52),与对照组正常脑组织对比有显著差异(P<0.001).②p53,C-erbB-2,PCNA异常表达与病理级别有明显相关性.病理Ⅲ,Ⅳ级的阳性率分别为80%(16/20),40%(8/20),100%(20/20),(P0.05);C-erbB-2阳性组,PCNA指数;0.361±0.27,阴性组PCNA指数;0.399±0.39,两组间亦无差异(P>0.05).④11例胶质增生组织有1例(9%)显示p53表达,C-erbB-2,PCNA无表达.随访3年,病变复发,病理证实为星形细胞瘤Ⅰ～Ⅱ级,C-erbB-2,PCNA表达.结果提示:①星形细胞瘤p53、C-erbB-2及PCNA的异常表达可作为星形细胞瘤恶性程度及病人预后的指标,以p53过度表达尤为重要;②3种抗体的联合应用对星形细胞瘤发病机理研究及预测早癌发生有一定价值,p53异常表达主要是影响星形细胞瘤的分化,而C-erbB-2对肿瘤进展早期起一定作用.③胶质增生的胶质细胞具有恶性表型.     

缺氧诱导因子-1的表达与脑膜瘤血管生成的关系

目的探讨缺氧诱导因子-1(HIF-1)的表达与脑膜瘤血管生成的关系。方法采用免疫组织化学方法检测48例脑膜瘤和10例正常脑膜组织中氧诱导因子-1α(HIF-1α)的表达,并用人原始造血细胞(CD34)抗体标记血管内皮细胞,计数脑膜瘤和正常脑膜组织中的微血管密度(MVD),对所得资料进行统计学分析。结果48例脑膜瘤组织中,HIF-1α阳性表达率为79%,其中弱阳性( ),阳性( ),强阳性( )表达率分别为33%,31%,15%;MVD为6~55,x±s为28±11;正常脑膜中无HIF-1α表达,MVD为4±1,明显低于肿瘤组织,差异有显著性(P<0.01)。HIF-1α阴性(-)表达者,MVD为11±5;呈弱( )、中( )及强阳性( )表达者,MVD分别为23±10、36±13及47±15;HIF-1α阳性表达程度与MVD呈正相关(rs=0.766,P<0.01)。结论HIF-1的表达与脑膜瘤血管生成密切相关,进一步研究HIF-1在脑膜瘤中的表达及调控血管生成的机制,可能为脑膜瘤的治疗开辟新途径。     

脑星形细胞瘤癌基因表达

52例星形细胞瘤应用免疫组化方法，检测癌基困P^53、C-erbB-2及增殖细胞核抗原(PCNA)的表达，结果发现④p53异常表达率为41.2%(24／52),C-erbB-2过度表达率为39%(20／52)，PCNA(PI>0．05)增殖指数为77%(40／52)，与对照组正常脑组织对比有显差异(P<0.01)。②p53，C-erbB-2，PCNA异常表达与病理级别有明显相关性。病理Ⅲ，Ⅳ级的阳性率分别为80%(16/20)，40%(8／20)，100%(20／20)，(P<0.001)；Ⅱ级的阳性率为33．3％(8／24)，50％(12／24)，83．3%(20／24)，(P<0．01)：Ⅰ级的阳性率为0：③p53阳性组，PCNA指数(PI)；0.552±0.322，阴性组PCNA指数为024±0．308，两组间无差异(P>0．05)；C-erbB-2阳性组，PCNA指数：0．361±0.27，阴性组PCNA指数：0．399±0.39，两组间亦无差异(P>0．05)．④11例胶质增生组织有1例(9％)显示p53表达，C-erbB-2，PCNA无表达：随访3年，病变复发，病理证实为星形细胞瘤Ⅰ～Ⅱ级，C-erbB-2，PCNA表达。结果提示：①星形细胞瘤p53、C-erbB-2及PCNA的异常表达可作为星形细胞瘤恶性程度及病人预后的指标，以p53过度表达尤为重要；②3种抗体的联合应用对星形细胞瘤发病机理研究及预测早癌发生有一定价值，p53异常表达主要是影响星形细胞瘤的分化，而C-erbB-2对肿瘤进展早期起一定作用。③胶质增生的胶质细胞具有恶性表型。     

紧密连接相关蛋白在脑膜肿瘤诊断中的意义

目的 探讨紧密连接相关蛋白在脑膜瘤、血管外皮瘤和孤立性纤维性肿瘤组织中的表达特点及其在鉴别诊断中的应用价值.方法 77例脑膜瘤组织标本,WHO I级脑膜瘤57例(纤维型10例、脑膜皮型10例、过渡型10例,血管瘤型10例、砂粒体型10例和微囊型7例);WHOⅡ级和WHOⅢ级脑膜瘤各10例,血管外皮瘤10例和孤立性纤维性肿瘤3例.分析不同肿瘤组织的形态学及免疫组织化学特征.结果 脑膜瘤标本上皮膜抗原(EMA)阳性表达率为85.71%(66/77),其中WHO Ⅰ级脑膜瘤为87.72%(50/57),以脑膜皮型最高,为100%,过渡型和血管瘤型最低,均为80%;WHOⅡ级脑膜瘤阳性表达率为90%(9/10);WHOⅢ级脑膜瘤为70%(7/10);血管外皮瘤和孤立性纤维性肿瘤均表达阴性.CD34、Bc1-2、S-100蛋白在3种肿瘤组织中均有不同程度表达,多数肿瘤组织和WHO Ⅲ级脑膜瘤组织波形蛋白和CD99呈阳性表达.Ki-67抗原标记指数在脑膜瘤标本中的表达水平随WHO分级的增加而逐渐升高,孤立性纤维性肿瘤表达水平较低,而血管外皮瘤表达水平较高.脑膜瘤组织紧密连接相关蛋白Claudin-1、-3、-4和-7阳性表达率为44.16% ～57.14%,其中WHO Ⅰ级脑膜瘤以脑膜皮型最高.而血管外皮瘤和孤立性纤维性肿瘤表达阴性.脑膜瘤、血管外皮瘤和孤立性纤维性肿瘤闭锁小带蛋白1均呈较高表达.结论 紧密连接相关蛋白Claudin-1、-3、-4和-7在脑膜瘤组织中呈阳性表达,而血管外皮瘤和孤立性纤维性肿瘤均表达阴性,特异性较强.提示,Claudin-1、-3、-4和-7可以作为脑膜肿瘤诊断与鉴别诊断的特异性标志.     

脑膜瘤Nestin表达与术后复发的关系

目的 探讨巢蛋白（Nestin）在脑膜瘤中的表达情况,分析其与脑膜瘤术后复发的关系。方法 收集2015年9月～2017年9月手术切除的169例脑膜瘤的肿瘤标本,采用免疫组化染色法检测肿瘤组织Nestin的表达水平。术后随访4年,采用多因素logistic回归模型分析脑膜瘤术后复发的危险因素。结果 169例中,术后复发43例,复发率为25.44%。169例脑膜瘤Nestin阳性表达率为73.37%(124/169),其中WHO分级Ⅰ级脑膜瘤Nestin阳性表达率[50.94%(27/53)]明显低于Ⅱ级、Ⅲ级脑膜瘤[分别为80.90%(72/89)、92.59%(25/27);P<0.001]。多因素logistic回归分析显示,Nestin表达阳性是脑膜瘤术后复发的独立危险因素（P<0.05）。结论 脑膜瘤Nestin表达与肿瘤WHO分级有关,检测Nestin表达可用于评估脑膜瘤术后复发的风险。     

人脑胶质瘤中PCNA的表达及临床意义

目的探讨增殖细胞核抗原(PCNA)在人脑胶质瘤中的表达与肿瘤生长、侵润、转移、复发的关系及在胶质瘤发生发展中的作用,拟为手术治疗及疗效提供客观依据。方法采用免疫组织化学染色方法检测正常脑组织及胶质瘤细胞中增殖细胞核抗原PCNA阳性表达率。结果对照脑组织增殖细胞核抗原表达阴性;不同级别胶质瘤细胞增殖细胞核抗原阳性表达率依次为WHOⅣ级100%(6/6)、WHOⅢ级94.44%(17/18)、WHOⅡ级62.50%(10/16)和WHOⅠ级42.86%(3/7);增殖细胞核抗原表达率与胶质瘤组织病理学分级呈正相关(rs=0.589,P=0.000);WHOⅢ-Ⅵ级与WHO I-Ⅱ级之间差异具有统计学意义(H=13.239,P=0.000)。结论胶质瘤组织中增殖细胞核抗原表达水平和肿瘤组织病理学分级呈正相关。提示,增殖细胞核抗原与胶质瘤恶性进展密切相关。     

脑胶质瘤的凋亡和相关基因Survivin的表达

目的明确Survivin在脑胶质瘤中的表达和细胞凋亡及微血管密度的相关性。方法检测Survivin在91例脑胶质瘤、20例颅内良性肿瘤的表达用免疫组化法,用流式细胞仪检测其表达和凋亡的关系。用CD34标记及图像定量分析微血管密度。结果Survivin在脑胶质瘤(WHO分级)中阳性率35?91(38.5%),随着脑胶质瘤的恶性程度增高,检出Survivin的阳性率就越高,其中I～II级为6?41(14.6%),III级为12?27(44.4%),IV级为17?23(73.9%)。III级以上恶性脑胶质瘤Survivin表达阳性显著高于II级以下脑胶质瘤(P<0.01)。20例颅内良性肿瘤仅1例表达(5%);Survivin表达强度和CD34标记及图像定量分析的微血管密度呈显著正相关(P<0.05);Survivin阳性比Survivin阴性患者术后生存期缩短(P<0.05)。结论Survivin对脑胶质瘤发生、恶化可能和抑制细胞凋亡、肿瘤血管的形成起重要的作用。     

脑膜瘤的增殖活性与生长激素受体的表达

目的探讨脑膜瘤中生长激素受体(GHR)及增殖细胞核抗原(PCNA)的表达及意义。方法应用免疫组化技术检测40例脑膜瘤的GHR和PCNA,并比较不同级别脑膜瘤GHR、PCNA的差异,分析GHR、PCNA对复发的影响以及GHR与PCNA的相互关系。结果脑膜瘤GHR阳性率为32.5%,PCNA标记指数(PCNALI)为55.4%±20.8%。非典型及恶性组的PCNALI显著高于良性组,复发组的PCNALI显著高于非复发组。GHR阳性与阴性组的PCNALI无统计学意义。结论GHR的表达对脑膜瘤的增殖无重要作用。PCNA作为脑膜瘤的增殖活性标记物,可为预测复发提供重要信息。     

脑胶质瘤细胞中HIF-1α表达及其与细胞凋亡、增殖关系

目的探讨缺氧诱导因子-1α(HIF-1α)在人脑胶质瘤中的表达及其与肿瘤细胞增殖、细胞凋亡和肿瘤恶性程度的关系。方法采用免疫组化法检测60例脑胶质瘤HIF-1α、增殖细胞核抗原(PCNA)的表达,用TUNEL法检测肿瘤细胞凋亡情况,对结果进行综合分析。结果HIF-1α总阳性表达率为73.3%,其中强表达19例(31.7%),中度表达14例(23.3%),弱表达11例(18.3%),不表达16例(26.7%);胶质瘤Ⅰ~Ⅱ级、Ⅲ~Ⅳ级HIF-1α的阳性率分别为50.0%、86.8%,组间有统计学差异(P<0.01)。脑胶质瘤标本PCNA及细胞凋亡均阳性,胶质瘤Ⅰ~Ⅱ级、Ⅲ~Ⅳ级PCNA阳性细胞数分别为54.9±8.2、121.6±15.6,凋亡细胞阳性数分别为85.4±10.4、52.1±7.6,比较均有显著性差异(P<0.01)。HIF-1α表达与肿瘤细胞的PCNA阳性数呈正相关(P<0.01),与肿瘤细胞的凋亡数无明显关系(P>0.05)。结论脑胶质瘤细胞HIF-1α表达与肿瘤的恶性程度有一定相关性;HIF-1α表达水平与肿瘤细胞增殖呈正相关,而与肿瘤细胞的凋亡无关。     

Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas

OBJECTIVE: Meningiomas for the most part are slow-growing benign tumors, but complete removal can be difficult and recurrence is an issue. The aim of this study was to re-evaluate tumors diagnosed as meningioma previously in our hospital, according to the latest World Health Organization classification. We also examined the relationships among parameters such as brain invasion, histological grade and Ki-67 and p53 expression in these tumors. MATERIALS AND METHODS: Meningioma biopsy specimens numbering 60 (48 grade I, 11 grade II, and 1 grade III tumors) were examined immunohistochemically using monoclonal antibodies for Ki-67 (MIB-1) and p53 protein. The MIB-1 labeling index (LI) for each tumor was calculated as a percentage based on the number of stained cells per total cells counted. The level of p53 expression in each sample was semiquantatively evaluated as < 1%, 1 - 10%, 10 - 70%, or > 70%. Any value > 1% was accepted as presence of p53 expression. RESULTS: Of the 60 meningiomas, 7 (11.7%) exhibited brain invasion. The mean MIB-1 LI values for the grade I and grade II tumors were 1.1% and 2.3%, respectively. The corresponding levels of p53 protein expression in these groups were 54.1% and 72.7%. The MIB-1 LI and the level of p53 expression in the one grade III meningioma were 6.7% and 10 - 70%, respectively. Histological grade was significantly correlated with MIB-1 LI and with p53 expression (p < 0.01 for both). Brain invasion was not correlated with histological grade, MIB-1 LI, or p53 expression. CONCLUSION: The results indicate that MIB-1 LI and p53 protein expression are good indicators of histological grade in meningioma and may be particularly valuable for distinguishing borderline atypical meningiomas. The number of cases was limited, but the findings also suggest that brain invasion is a prognostic parameter independent of grade, MIB-1 LI and p53 expression.     

Cytoplasmic iron deposition is associated with the expression of oxidative DNA damage marker in meningiomas

Angiomatous meningiomas are rare meningioma subtypes, which are characterized by abundant, well‐formed vessels. We encountered two cases of newly diagnosed angiomatous meningiomas exhibiting tumor cells with brown pigments, which were histochemically proven to be iron. In an attempt to understand its pathological significance, we assessed this unusual finding in representatives for each grade of meningiomas and immunoexpression of transferrin receptor (CD71) and the oxidative DNA damage marker, 8‐hydroxy‐2′‐deoxyguanosine (8‐OHdG). Iron deposition in the tumor cells was observed in 8/15 (53%) angiomatous meningioma cases, 2/6 (33%) microcystic meningiomas and 2/20 (10%) meningothelial meningiomas, which included clustered microvessels, but not in fibrous, atypical or anaplastic meningiomas (P = 0.001). Cytoplasmic CD71 expression was largely negative in angiomatous meningioma cases, but positive in meningothelial and high‐grade meningiomas, suggesting that the transferrin‐dependent iron transporter was involved in iron uptake in meningiomas. Nuclear expression of 8‐OHdG was observed in ≥50% of the tumor cells in all 15 cases of angiomatous meningioma and was associated with the presence of regressive histopathological findings, such as hyalinized vessels and cystic changes. In addition, the fraction of iron‐containing tumor cells was correlated to those expressing 8‐OHdG (P = 0.005). Our finding indicates that cytoplasmic iron deposition in tumor cells is characteristic of highly vascularized benign meningiomas and related to increased oxidative DNA damage markers.     

Survivin在星形细胞瘤中的表达及其与肿瘤增殖活性的相关分析

目的:探讨Survivin、Ki67在星形细胞瘤中的表达规律和意义。方法:采用免疫组织化学SP法,检测10例正常脑组织和59例星形细胞瘤中Survivin蛋白及ki67的表达,并结合病理特点进行分析。结果:正常脑组织中未见Survivin表达,星形细胞瘤中Survivin表达阳性率为64.4%.组织学分级之间差异显著(P<0.05)。此外Survivin的表达还与Ki67呈明显相关(P<0.05)。结论:Survivin在星形细胞瘤中高表达,与星形细胞瘤的恶性程度、增殖活性密切相关,可望成为诊断治疗的新靶点。     

IGF-1表达与人脑膜瘤细胞增殖活性关系

目的探讨IGF-1在人脑膜瘤中的表达与脑膜瘤细胞增殖活性之间的关系。方法应用免疫组化SP法检测42例脑膜瘤组织、7例正常硬脑膜中IGF-1和增殖细胞核抗原(PCNA)的表达情况,结果进行统计学分析。结果 IGF-1在正常硬脑膜组、WHO I、II和III级脑膜瘤组的表达强度不等,分别为0%、(15.7±12.8)%、(47.2±11.7)%和(62.9±12.9)%,其差异均具有统计学意义(P<0.05)。PCNA在同样四个组别中的PCNA-LI值分别为0%、9.6±5.4%、30.6±5.6%和48.7±15.1%,其差异亦均具有统计学意义(P<0.05)。相关分析结果显示:IGF-1与PCNA-LI两者呈正相关(r=0.8594)。结论 IGF-1表达强度与脑膜瘤细胞增殖活性有关,二者在脑膜瘤的发生、增殖和恶化过程中可能起协同作用,其详细机制有待进一步研究。     

Clinical and histological features of multiple meningiomas compared with solitary meningiomas

Between 1991 and 2002, 456 patients with an intracranial meningioma were treated. Thirty-nine of these had more than one meningioma (8.6%). The mean age was 58 years (27-85 years). Sex distribution was 8.8:1 (35 female, four male). There was no associated spinal meningioma. No patient had neurofibromatosis. In 19 patients all meningiomas were removed. Twelve showed the same histology, seven had different histological features. In the remaining 20 patients only the symptomatic meningioma was removed. Recurrences occurred in 11 patients (28.2%). Six patients died during follow-up. Multiple meningiomas have their own clinical features. Besides a high female preponderance, PR expression was stronger in multiple meningiomas than in solitary meningiomas while p53 status and MIB-1 LI were similar between the two groups. Progesterone receptor, p53 status and MIB-1 LI were valuable markers for predicting a patient's outcome in multiple meningiomas. The number of meningiomas is growing in patients with recurrent meningiomas.     

Analysis of PCNA, Ki67, AgNOR and p53 expression in brain glial tumors

BACKGROUND AND PURPOSE: The aim of this study was to evaluate clinical usefulness of proliferating cell nuclear antigen (PCNA), Ki67 antigen, p53 protein and silver-binding nucleolar organizer regions (AgNOR) in brain glial tumors. MATERIAL AND METHODS: The investigation of PCNA, Ki67 and p53 was carried out on a group of 120 patients with glial tumors operated on at the Neurosurgical Department of Wroclaw Medical University including 63 patients operated again because of recurrence. AgNOR was evaluated on a group of 64 patients including 38 patients operated again. Classical histological tests, immunohistochemical tests for PCNA, p53 and Ki67 activity with monoclonal antibodies (DACO) and histochemical tests for AgNOR were performed on every specimen of tumor tissue. The level of 40% for PCNA, 2.75 (equal to median) for AgNOR and 5% for Ki67 and p53 was adopted as significant. RESULTS: Mean expression of PCNA of glial tumors grade I and II was 32%, grade III and IV - 44% (p<0.05). Mean expression of AgNOR was 1.88 and 3.16 (p=0.00001), respectively. Average PCNA expression in recurrent tumors to 12 months was 52.7% and for later recurrences - 35.4% (p<0.05). Average expressions of AgNOR were 3.38 and 2.68 (p<0.05), respectively. Differences of Ki67 and p53 expressions were not significant. CONCLUSIONS: PCNA and AgNOR expressions correlate with proliferative activity, growth rate and histological malignancy, reaching high values in highly malignant and early recurrent tumors. Antigens Ki67 and p53 do not seem to be predictive markers of glial tumors.     

100例脑肿瘤中p53基因突变与P53蛋白积聚的研究

目的:研究不同类型脑肿瘤中的p53基因突变与P53蛋白积聚及其相关性。方法:采用聚合酶链反应-单链构象多态性(PCR-SSCP)分析及免疫组化法检测100例脑肿瘤p53基因突变及蛋白表达。结果:p53基因突变率为11%(11/100),其中高恶度胶质瘤为37.5%(6/16),低恶度胶质瘤4.3%(1/23),脑膜瘤6.9%(2/29),转移瘤40.0%(2/5)。P53蛋白表达阳性率为22%(22/100),其中高恶度胶质瘤为62.5%(10/16),低恶度胶质瘤为26.1%(6/23),脑膜瘤10.3%(3/29),转移瘤60%(3/5);其他肿瘤均未发现p53基因突变或蛋白表达。P53蛋白表达阳性的22例中伴有p53基因突变者11例,多见于高恶度肿瘤。结论:p53基因失活在脑肿瘤恶性进展过程中起重要作用。p53基因突变与P53蛋白积聚相关,但并非唯一因素。     

Significance of cyclin D1 expression in meningiomas: a preliminary study.

Forty-four evaluable patients with intracranial meningiomas were assessed for the expression of the cell-cycle regulator cyclin D1 and of proteins involved in proliferation and apoptosis such as PCNA, MIB-1, p53 and bcl-2. Analyses were carried out by western blot and immunohistochemistry after immediate processing of fresh tumor specimens. By western blot, expression of cyclin D1 significantly correlated with p53 (p=0.02) and with proliferative activity, as assessed by PCNA expression (p=0.0009). By immunohistochemistry, a significant relationship between cyclin D1 and the proliferation marker MIB-1 was confirmed (p=0.05), whereas significance with bcl-2 expression was not found (p=0.01). Moreover, although the association with tumor grade appeared of borderline statistical significance (p=0.07), all the grade II/III meningiomas showed increased expression of cyclin D1 and high proliferative activity. In conclusion, data from this preliminary study seem to suggest a potential value of the combined expression of cyclin D1 and proliferation indicators in defining subgroups of meningiomas with a more aggressive biological behavior.     

Cell‐adhesion molecules in human meningiomas: correlation with clinical and morphological data

Integrins form a family of cell adhesion molecules. CD44 glycoproteins are found in a wide variety of isoforms; the most common, CD44s (standard) is widely distributed, and functions as an adhesion molecule. In this study, we have investigated immunohistochemically the distribution of some VLA integrins (α2, α5 and α6 chains of β1 integrins) and CD44s in 44 meningioma specimens and normal arachnoid villi. Meningiomas were of meningothelial (16), transitional (13) and fibroblastic (15) subtypes. There were 13 grade I, 19 grade II and 12 grade III (27%). Immunoprecipitates were quantified by image analysis and correlated with clinical (age, sex, location) and morphological data (histological subtypes and grades). VLA α5 chain was expressed by normal arachnoid villi (mainly cap cells) and by 42 out of 44 meningioma specimens. Expression was lower in fibroblastic meningiomas (P=0.02). VLA α2 and α6 chains were not observed in normal arachnoid villi. VLA α2 was expressed by 15 meningiomas, VLA α6 by 10. Interestingly, meningiomas expressing either VLA α2 or α6 were usually of grade III (P≤0.05). CD44s was found on various parts of arachnoid villi and in all meningiomas although expression was higher in meningothelial and transitional than in fibroblastic (P≤0.001). These results show that VLA α5 and CD44s are widely expressed by arachnoid villi and meningiomas, in contrast to VLA α2 and VLA α6. It was noted that high grade meningiomas (III) express VLA α2 and α6 suggesting that changes in integrin pattern expression are a feature of these meningiomas. Moreover, strong CD44s expression characterizes meningothelial and transitional meningiomas. Previous studies have shown that high NCAM expression is a feature of fibroblastic meningiomas whereas meningothelial and transitional meningiomas expressed mainly E-Cadherin, and that polysialylated NCAM expression was restricted to high grade meningiomas. Taken together these features suggest that each cell adhesion molecule has a characteristic pattern of expression according to meningioma subtype and grade. No correlation was seen between integrins and CD44s expression and clinical data.     

Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications

The second most frequently reported genetic abnormalities in meningiomas after 22q loss are deletions of 1p and 14q. To assess the potential diagnostic and prognostic utility of these chromosomal alterations, we studied 180 well-characterized meningiomas using dual-color fluorescence in situ hybridization (FISH) with DNA probes localized to 1p32, 1p36, 14q13, and 14q32. Our cohort consisted of 77 benign (grade I), 74 atypical (grade II), and 29 anaplastic (grade III) meningiomas. Benign and atypical meningiomas were further stratified into subsets of recurring (despite gross total resection) vs non-recurring (at least 10 yr of follow-up) and mitotically active vs brain invasive subsets, respectively. Losses of 1p and 14q losses were identified in 23% and 31% of benign, 56% and 57% of atypical, and 75% and 67% of anaplastic meningiomas, respectively (p < 0.001 for 1p; p = 0.004 for 14q). Combined 1p/14q deletions were encountered in 7% benign. 39% atypical, and 63% anaplastic meningiomas (p < 0.001). Benign non-recurring meningiomas were less likely to harbor 14q deletions than recurring examples (17% vs 50%, p = 0.013). There was a trend for anaplastic meningiomas with 14q deletions and atypical meningiomas with combined 1p/14q deletions to have poorer overall survivals, though neither reached statistical significance. We conclude that 1p and 14q deletions are highly associated with increasing histologic grade and play an important role in meningioma tumor progression. Furthermore, 14q FISH analysis may aid in assessing recurrence risk in histologically benign meningiomas.